Cardiac biomarkers, cardiotoxicity, and active collaboration: Is this the final frontier or the wave we should catch?

Journal of the American College of Cardiology

Volumn 63, Issue 8, 2014, Pages 817-818

  Lenihan, Daniel J ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

cardio oncology; chemotherapy cardiotoxicity; trastuzumab cardiotoxicity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; MYELOPEROXIDASE; TROPONIN I; ANTINEOPLASTIC AGENT; CARVEDILOL; ENALAPRIL;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIAC IMAGING; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; NOTE; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT PLANNING; CARDIOLOGIST; CHEMOPROPHYLAXIS; EARLY DIAGNOSIS; INTERDISCIPLINARY COMMUNICATION; ONCOLOGIST; PROTEIN BLOOD LEVEL;

CARDIO-ONCOLOGY; CHEMOTHERAPY CARDIOTOXICITY; TRASTUZUMAB CARDIOTOXICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; PEROXIDASE; TROPONIN I;

EID: 84896703111     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.10.060     Document Type: Editorial

References (12)

1. D.J. Lenihan, and D.M. Cardinale Late cardiac effects of cancer treatment J Clin Oncol 30 2012 3657 3664
2. J. Chen, J.B. Long, A. Hurria, C. Owusu, R.M. Steingart, and C.P. Gross Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Coll Cardiol 60 2012 2504 2512
3. E.J. Bowles, R. Wellman, and H.S. Feigelson et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study J Natl Cancer Inst 104 2012 1293 1305
4. A. Hossain, A. Chen, and P. Ivy et al. The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting Heart Fail Clin 7 2011 373 384
5. B. Ky, M. Putt, and H. Sawaya et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab J Am Coll Cardiol 63 2014 809 816
6. D. Cardinale, A. Colombo, and R. Torrisi et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
7. J. Januzzi, and G.M. Felker Surfing the biomarker tsunami at JACC: Heart Failure J Am Coll Cardiol HF 1 2013 213 215
8. M. Ledwidge, J. Gallagher, and C. Conlon et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial JAMA 310 2013 66 74
9. A.F. Hernandez Preventing heart failure JAMA 310 2013 44 45
10. X. Bosch, M. Rovira, and M. Sitges et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 2013 2355 2362
11. D.J. Lenihan, D. Cardinale, and C.M. Cipolla The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society Prog Cardiovasc Dis 53 2010 88 93
12. W.J. van Heeckeren, S. Bhakta, and J. Ortiz et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24 2006 1485 1488 (Pubitemid 46638767)